Evidence map›Paper›PMID 41537306›Full record

ArticleDisease models & mechanisms2026

Immunopathological outcomes are isolate dependent in chronic Mycobacterium avium complex pulmonary disease.

Timothy D Shaw, Ha Lam, Taru S Dutt, Camron M Pearce, Ilham Alshiraihi, Andres Obregon-Henao, Marcella Henao-Tamayo, Sara E Maloney Norcross, Bernd Meibohm, Mary Jackson and 1 more

Abstract read
In one paragraph

Article in Disease models & mechanisms, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Timothy D ShawWellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast BT9 7BL, UK.ORCID 0000-0003-0813-5391
Ha LamMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523-1682, USA.
Taru S DuttMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523-1682, USA.
Camron M PearceMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523-1682, USA.
Ilham AlshiraihiMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523-1682, USA.
Andres Obregon-HenaoMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523-1682, USA.
Marcella Henao-TamayoMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523-1682, USA.
Sara E Maloney NorcrossTechnology Advancement and Commercialization, RTI International, Research Triangle Park, NC 27709, USA.
Bernd MeibohmDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Mary JacksonMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523-1682, USA.
Mercedes Gonzalez-JuarreroMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523-1682, USA.ORCID 0000-0002-4045-2365

Funding

Inhaled tigecycline therapy for pulmonary M. abscessus infectionsR01AI155922 · NIAID · COLORADO STATE UNIVERSITY · PI GONZALEZ-JUARRERO, MERCEDES, MALONEY, SARA ELIZABETH · 2021 to 2025
$3.6M
Repurposing antimalarials for the treatment of NTM infectionsR01AI170504 · NIAID · COLORADO STATE UNIVERSITY · PI JACKSON, MARY · 2022 to 2025
$2.6M
Vectra Polaris microscope imaging systemS10OD030263 · OD · COLORADO STATE UNIVERSITY · PI GONZALEZ-JUARRERO, MERCEDES · 2021 to 2021
$452k
Dowager Countess Eleanor Peel TrustNIAID NIH HHS R01 AI155922NIAID NIH HHS R01 AI170504NIH HHS R01AI155922NIH HHS R01 AI170504NIH HHS S10 OD030263NIH HHS S10OD030263Queen's University Belfast
6 · The paper itself

Abstract

Novel treatment strategies are urgently needed to combat Mycobacterium avium complex (MAC) pulmonary disease (PD). Animal models are important for screening therapeutic strategies, but their ability to reproduce human-like immunopathology and impaired respiratory function is poorly characterised. We modelled chronic lung infection in BALB/c mice over 20 weeks with three isolates of MAC (MAC101, MAC104 and MAC2285R) to compare bacterial growth, histological injury, immune cellular dynamics and respiratory function. We found that MAC101 caused a proliferative infection over 20 weeks, associated with a strong adaptive response, progressive granulomatous inflammation and increasing respiratory effort. For MAC104, lung bacterial burden rose initially but fell after week 12, accompanied by increased regulatory T-cell response and stabilisation of pathological and respiratory changes. By contrast, MAC2285R caused a low-virulence, non-proliferative infection associated with a strong myeloid cell response, modest histopathological change and increased respiratory effort. Immune cell dynamics in chronic murine MAC-PD correlate with bacterial burden and pathology and are strongly MAC-isolate dependent. These findings provide a spectrum of quantifiable and clinically relevant disease outcomes to facilitate the preclinical screening of novel antimicrobial and host-directed therapies for MAC-PD.

Indexed as

Lung DiseasesMycobacterium avium ComplexMycobacterium avium-intracellulare InfectionAnimalsChronic DiseaseDisease Models, AnimalFemaleLungMice, Inbred BALB CVirulenceAnimal modelHistopathologyImmunologyMycobacterium avium complexNon-tuberculous mycobacteria

Identifiers

PMID41537306
PMCPMC12893035

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.